Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

A once-daily oral nonpeptide GLP-1 conferred significant improvements in body weight, HbA1c and other cardiometabolic ...

Last year, China-based Jiangsu Hengrui Pharmaceuticals overtook the U.K.’s AstraZeneca as the top clinical trial sponsor in ...

PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

Get the latest S&P 500 healthcare stock winners & losers, major earnings beats, profit forecasts, and legal news for key companies.

Eli Lilly will submit orforglipron to be part of FDA’s new national priority voucher program, according to a new report. 1 The company believes it to be a strong candidate for the program.